Diabetic Neuropathy: Selected Treatments

Aetna covers percutaneous electrical stimulation for diabetic neuropathy only after failure of conventional pharmacologic treatments (e.g., pregabalin, amitriptyline/duloxetine, opioids, capsaicin) but limits use to 4 weeks or less; dorsal column (spinal cord) stimulation and surgical decompression for entrapment are covered when the CPB 0194/this CPB selection criteria are met and appropriate CPT/HCPCS neurostimulator codes are used. Aetna considers acupuncture, aldose reductase inhibitors, angiotensin II type 2 receptor antagonists, autologous bone marrow–derived stem cells and other listed therapies experimental/investigational and not medically necessary for diabetic neuropathy.

"Aetna considers the following interventions experimental and investigational for the treatment of diabetic neuropathy ."

Sign up to see full coverage criteria, indications, and limitations.